Monthly Archives: December 2013

Fewer Small Public Biotechs Today

Fig2-size-2008-vs-2013-115x76

A lot can happen in six years. The number of active biotech companies currently trading on US exchanges is now only 300. At the start of 2008, there were almost 400 active companies.   The net decrease in the number of active companies since 2008 is 24%. Had it not been for all the IPO activity we have seen this year, the decrease would have been substantially more. In fact, only 55% of the original Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

VIDEO: Public Policies to Promote the Innovation Economy

SBIR Reauthorization Moves Forward

What can lawmakers do to make the US more competitive globally and encourage investment in groundbreaking R&D companies? Earlier today, the Coalition of Small Business Innovators held a forum at the National Press Club to discuss proposals that would do just that. Moderated by Paul Stimers, a partner with K&L Gates, the panel included Doug Doerfler, president and CEO of MaxCyte, Ed Mathers, a partner with venture capital firm New Enterprise Associates, Katherine Hamilton, policy Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,

FDA Check-Up: Drug Development and Manufacturing Challenges

Paul Hastings

I have over 27 years of experience in the biotechnology and pharmaceutical industry. My current company, OncoMed Pharmaceuticals, is working at the cutting edge of oncology research, focused on antibodies that target a specific set of cells within tumors, known as tumor initiating cells, that drive the growth of the tumor and can differentiate into various cell types within the tumor. Currently, we have five products in clinical development in over 13 completed or ongoing Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Emerging Company Policy Deconstructed: Fostering Innovation Act (H.R. 2629)

scientists115x76

In a nutshell: Representative Michael Fitzpatrick (R-PA) introduced H.R. 2629, the Fostering Innovation Act, to update SEC filing status classifications for public companies and help ease regulatory burdens on emerging companies and reduce the bureaucratic hurdles and red tape that lengthen the time to bring cures from discovery to patient. Why you should care: SEC Rule 12b-2 establishes three classifications for public companies to determine their filing status, which include large accelerated filers (companies with Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

BIO Joins Partners for Healthy Dialogues

Jim Greenwood

The Biotechnology Industry Organization (BIO) recently joined the Partners for Healthy Dialogues effort. Dialogues+ had the opportunity to ask Jim Greenwood, President and CEO of BIO, about why BIO joined the effort, the importance of collaboration and preparing for the Physician Payments Sunshine Act. “BIO and our members support transparency in the life science industry and in the relationships between industry and physicians. We also strongly believe in the value of such relationships for the Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , ,